Director Appointment - Reece O’Connell
TruScreen Group Limited (NZX/ASX:TRU) (TruScreen or the Company, a global leader in Al-enabled cervical cancer screening, is pleased to announce the appointment of Mr. Reece O'Connell as an independent Non-Executive Director of the Company with effect from 3 June 2026.
Mr. O'Connell is an experienced board Chairman, Non-Executive Director and fund manager with deep experience across the biotechnology investment and commercialisation lifecycle, spanning asset selection, capital formation, governance, and international market development.
Mr. O'Connell has an MBA (University of Canberra), Bachelor of Business, Finance (Murdoch University) and a Graduate Diploma of Financial Planning (Kaplan). Mr. O'Connell is currently Chairman of Nexsen Limited (ASX:NXN), Non-Executive Director of RooLife Group (ASX:RLG) and Funds Manager of Summit Funds Management, Biotechnology Fund.
As foreshadowed in the NZX/ASX announcement dated 1 April 2026, Mr. Chris Horn, who has served as a Director of the Company for 13 years retires as at today's date.
Non-Executive Chairman Tony Ho commented,
"Reece has significant relevant experience in Biotech and we welcome him to the TruScreen Board at a time of significant opportunity. The Board will continue to ensure that it has the appropriate skill mix to guide the Company's next phase of growth.
We thank Chris for a significant contribution over many years, and wish him well in retirement."